Amarin Corp Plcuk (AMRN) Current Assets (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Current Assets of $626.0 million for Q1 2026, up 9.24% year-over-year from $573.1 million in Q1 2025, and down 3.67% quarter-over-quarter from $649.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Current Assets (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Current Assets data on file, last reported at $626.0 million in Q1 2026.
- Current Assets for Q1 2026 came in at $626.0 million, up 9.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $626.0 million (up 9.24% YoY), and the FY2025 annual result was $649.9 million, up 9.15% from the prior year.
- Current Assets slipped to $626.0 million in Q1 2026 per AMRN's latest filing, from $649.9 million in the prior quarter.
- Over five years, Current Assets peaked at $772.6 million in Q1 2022 and troughed at $573.1 million in Q1 2025.
- A 5-year average of $671.7 million and a median of $686.5 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2026: Current Assets fell 28.71% in 2022, then rose 9.24% in 2026.
- A 5-year view of Current Assets shows it stood at $689.1 million in 2022, then increased by 5.21% to $725.0 million in 2023, then declined by 17.87% to $595.4 million in 2024, then grew by 9.15% to $649.9 million in 2025, then retreated by 3.67% to $626.0 million in 2026.
- Business Quant data shows AMRN's Current Assets at $626.0 million in Q1 2026, $649.9 million in Q4 2025, and $628.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 23.94 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 54.84 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 59.17 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 33.53 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 27.21 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | 626.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 626.00 Mn |
| Dec 31, 2025 | 649.88 Mn |
| Sep 30, 2025 | 628.30 Mn |
| Jun 30, 2025 | 606.80 Mn |
| Mar 31, 2025 | 573.06 Mn |
| Dec 31, 2024 | 595.40 Mn |
| Sep 30, 2024 | 650.22 Mn |
| Jun 30, 2024 | 701.80 Mn |
| Mar 31, 2024 | 687.90 Mn |
| Dec 31, 2023 | 724.98 Mn |
| Sep 30, 2023 | 717.51 Mn |
| Jun 30, 2023 | 706.50 Mn |
| Mar 31, 2023 | 683.80 Mn |
| Dec 31, 2022 | 689.10 Mn |
| Sep 30, 2022 | 686.52 Mn |
| Jun 30, 2022 | 719.10 Mn |
| Mar 31, 2022 | 772.62 Mn |
| Dec 31, 2021 | 878.73 Mn |
| Sep 30, 2021 | 963.03 Mn |
| Jun 30, 2021 | 996.00 Mn |